TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
An autopsy study of 230 people with Parkinson’s disease found higher rates of Alzheimer’s amyloid pathology in women, particularly among women with Parkinson’s disease dementia. Researchers found no sex difference in tau pathology or levels of cognitive impairment; the study does not establish whether amyloid caused dementia or whether Alzheimer’s treatments could help these patients.
A study of 230 autopsy cases involving people with Parkinson’s disease found that women had higher rates of Alzheimer’s-related amyloid pathology than men, with the difference particularly evident among women who had Parkinson’s disease dementia. Published in the Journal of Parkinson’s Disease, the findings point to a sex difference in the overlap between neurodegenerative conditions, but do not show that amyloid caused dementia or that Alzheimer’s drugs would benefit people with Parkinson’s.
Researchers analyzed brain tissue from cases in the Arizona Study of Aging and Neurodegenerative Disorders and its Brain and Body Donation Program. Their report, by N. Dunckley and colleagues, examined differences between women and men with Parkinson’s disease, including the presence of Alzheimer’s-related changes in the brain.
The reported difference concerned amyloid pathology, which includes protein deposits associated with Alzheimer’s disease. The study did not find a sex difference in tau pathology or in levels of cognitive impairment. Those results distinguish the amyloid finding from other disease-related brain changes and clinical measures assessed by the researchers.
The study concerns findings in donated brains examined after death, rather than a treatment trial or a test designed to predict an individual patient’s future. The authors’ paper, “Greater burden of Alzheimer’s Co-pathology in women with Parkinson’s disease dementia,” appeared in volume 16 of the journal, pages 1191–1200. Its DOI is 10.1177/1877718X261470295.
Why Amyloid Overlap Matters
Parkinson’s disease and Alzheimer’s disease are distinct diagnoses, but more than one type of disease-related change can be present in the same brain. The study adds evidence that this mixed pathology may differ by sex among people with Parkinson’s, and that amyloid deserves closer examination in research involving Parkinson’s disease dementia.
That could affect how researchers design studies and interpret cognitive symptoms in people with Parkinson’s. If some patients have substantial Alzheimer’s-related changes alongside Parkinson’s, future research may need to account for those changes when investigating dementia, disease progression or potential treatments. The present study does not establish how amyloid relates to symptoms in each person, however, and cannot show that targeting amyloid would improve cognition.
Anti-amyloid medicines are approved for certain patients diagnosed with Alzheimer’s disease, according to the source report. Their approval for some Alzheimer’s patients does not mean they are approved or proven effective for Parkinson’s disease dementia. Any possible use in that group remains a research question, not a treatment recommendation.
Products Worth Considering
Fitbit Sense 2 Health and Fitness Smartwatch, Shadow Grey/Graphite
Garmin Venu 3S GPS Smartwatch with AMOLED Display, Soft Gold and French Gray Silicone Band
BowFlex Results Series SelectTech Dumbbells
As an affiliate, we earn on qualifying purchases.
Parkinson’s and Mixed Brain Pathology
The researchers’ findings build on a familiar observation in brain-donation research: a person’s diagnosis during life may not capture every disease-related change found at autopsy. Erika Driver-Dunckley, a Mayo Clinic movement disorder neurologist and one of the study’s lead researchers, said that multiple pathologies are often identified in donated brains, including cases initially associated with a single diagnosis.
Driver-Dunckley said the notable result was not simply that Parkinson’s and Alzheimer’s-related changes can coexist, but that the researchers observed a sex difference in amyloid pathology. The report focuses on people with Parkinson’s disease, including a subgroup with Parkinson’s disease dementia; it is not a comparison of all women and men in the general population.
The study was published in the Journal of Parkinson’s Disease and used tissue from the AZSAND and BBDP programs. Because it is based on autopsy cases, its findings describe the examined sample. They should not be read as a population-wide estimate of how often women with Parkinson’s have Alzheimer’s pathology.
“In women, particularly those with Parkinson’s disease dementia, they had higher rates of Alzheimer’s amyloid pathology.”
— Erika Driver-Dunckley, Mayo Clinic movement disorder neurologist and study lead researcher
Limits of the Autopsy Findings
The reported results do not establish why women in the sample had higher rates of amyloid pathology, whether the difference applies beyond the donated-brain cases, or how closely the pathology tracked symptoms during life. The source report provides the total sample size but does not give the sex-specific counts, the size of the difference, or detailed measures of statistical uncertainty.
It is also unclear whether amyloid contributed to cognitive impairment in the patients studied. Researchers reported no sex difference in levels of cognitive impairment, despite the difference in amyloid pathology. The available information does not establish a causal link between amyloid and Parkinson’s disease dementia.
Finally, the findings do not test anti-amyloid medicines in people with Parkinson’s disease dementia. Whether patients with both Parkinson’s and increased amyloid pathology could benefit from those treatments has not been answered by this study.
Research Needed Before Treatment Claims
The immediate next step is further research to determine whether the amyloid difference can be replicated in other groups and how it relates to cognitive symptoms over time. Studies involving people assessed during life, alongside brain-pathology data where available, could help clarify whether amyloid identifies a meaningful subgroup of Parkinson’s disease dementia.
Researchers may also investigate whether anti-amyloid treatments warrant testing in carefully selected patients with Parkinson’s and confirmed amyloid pathology. The current report raises that possibility but does not say that a trial is underway, identify a planned next milestone, or support changing treatment. Patients should consult a qualified health professional about medical decisions.
Key Questions
What did the study find?
In an autopsy study of 230 people with Parkinson’s disease, women had higher rates of Alzheimer’s-related amyloid pathology than men, particularly in the group with Parkinson’s disease dementia.
Did women also have more tau pathology?
No sex difference was reported in tau pathology. The researchers also reported no difference between women and men in levels of cognitive impairment.
Does this mean Alzheimer’s disease caused the dementia?
No. The study found co-occurring amyloid pathology but does not establish that amyloid caused dementia or explain how the pathology related to symptoms in each person.
Could anti-amyloid drugs help people with Parkinson’s disease dementia?
The study did not test those medicines in people with Parkinson’s disease dementia. Whether they could benefit some patients with increased amyloid pathology remains a question for future research, not an established treatment.
Source: news-medical.net
